Education
About Us
Working with TipRanks
Follow Us
Twist Bioscience Corp (TWST)
NASDAQ:TWST
TWST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.07 - $55.33
Previous CloseN/A
Volume152.02K
Average Volume (3M)1.74M
Market Cap
$1.92B
Enterprise Value$2.08B
Total Cash (Recent Filing)$250.80M
Total Debt (Recent Filing)$78.15M
Price to Earnings (P/E)―
Beta2.45
Next Earnings
Nov 24, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.33
Shares Outstanding60,360,924
10 Day Avg. Volume1,926,766
30 Day Avg. Volume1,744,711
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue5.73
Enterprise Value/Gross Profit11.65
Enterprise Value/Ebitda-16.83
Forecast
1Y Price Target
$37.00Price Target Upside18.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Customer IncentivesTWST has waived Express surcharge for academics and rolled out TWST wallet so customers can bank funds, helping TWST gain customers.
Growth PotentialNGS remains a key driver into the future as MRD is expected to more materially drive growth.
Market PositionTwist remains largely insulated from broader Tools headwinds due to minimal revenue exposure from China, growing Academia revenues, and minimal tariff impact.
Bears Say
Revenue GuidanceTWST narrowed their guide downward to $374M-$376M from $372M-$379M.
Revenue PerformanceShares of TWST have been under pressure after FQ3 topline revenues were in line with guidance despite investor hopes for a clean beat.
Segment PerformanceQuestions about growth for the SynBio and Biopharma segments remain given light FQ3 revenues.
Twist Bioscience News
TWST FAQ
What was Twist Bioscience Corp’s price range in the past 12 months?
Twist Bioscience Corp lowest stock price was $24.07 and its highest was $55.33 in the past 12 months.
What is Twist Bioscience Corp’s market cap?
Twist Bioscience Corp’s market cap is $1.92B.
When is Twist Bioscience Corp’s upcoming earnings report date?
Twist Bioscience Corp’s upcoming earnings report date is Nov 24, 2025 which is in 43 days.
How were Twist Bioscience Corp’s earnings last quarter?
Twist Bioscience Corp released its earnings results on Aug 04, 2025. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of -$0.519 by $0.849.
Is Twist Bioscience Corp overvalued?
According to Wall Street analysts Twist Bioscience Corp’s price is currently Undervalued.
Does Twist Bioscience Corp pay dividends?
Twist Bioscience Corp does not currently pay dividends.
What is Twist Bioscience Corp’s EPS estimate?
Twist Bioscience Corp’s EPS estimate is -0.41.
How many shares outstanding does Twist Bioscience Corp have?
Twist Bioscience Corp has 60,360,924 shares outstanding.
What happened to Twist Bioscience Corp’s price movement after its last earnings report?
Twist Bioscience Corp reported an EPS of $0.33 in its last earnings report, beating expectations of -$0.519. Following the earnings report the stock price went down -10.303%.
Which hedge fund is a major shareholder of Twist Bioscience Corp?
Currently, no hedge funds are holding shares in TWST
Twist Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.00 (18.63% Upside)
$37.00 (18.63% Upside)
Blogger Sentiment
Bullish
TWST Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.0%
Last 30 Days ▲ 15.0%
Last 30 Days ▲ 15.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.11%
12-Months-Change
Fundamentals
Return on Equity
-17.58%
Trailing 12-Months
Asset Growth
0.86%
Trailing 12-Months
Company Description
Twist Bioscience Corp
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
TWST Company Deck
TWST Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook with record revenue growth, significant improvements in gross margin, and strong performance in the NGS segment. However, there were challenges noted in specific regions and slower-than-expected growth in SynBio. Despite these, the company remains optimistic about future growth opportunities, especially in SynBio and NGS, and is on track to achieve adjusted EBITDA breakeven.View all TWST earnings summariesTWST Stock 12 Month Forecast
Average Price Target
$37.00
▲(18.63% Upside)
Technical Analysis
Ownership Overview
2.55% Insiders
28.03% Mutual Funds
0.02% Other Institutional Investors
41.19% Public Companies and Individual Investors